Modern management of arrhythmias

M C S Hall, D M Todd

The specialist management of arrhythmias has changed significantly over the past decade. This article outlines current management strategies for atrial flutter and atrial fibrillation, with particular emphasis on curative strategies with catheter ablation and the recent data on rhythm compared with rate control strategies. The expanding role of catheter ablation in the treatment of a wide variety of supraventricular and ventricular arrhythmias is discussed. The current evidence for implantable cardioverter defibrillators in the prevention of sudden cardiac death is summarised. The article also highlights the increasing recognition of a number of inherited syndromes that predispose to sudden cardiac death (for example, Brugada and long QT syndromes).

The management of cardiac arrhythmias has changed tremendously over the past decade. During this time the two principal tools of modern arrhythmia management, catheter ablation and device therapy, have evolved to treat many conditions. Catheter ablation has moved from being a treatment considered only for patients with refractory arrhythmias to a first line treatment. In addition it has expanded into the treatment of the “big two” arrhythmias—atrial fibrillation (AF) and atrial flutter. Device therapy has moved from bradycardia pacing into more complex areas such as the implantable cardiac defibrillator (ICD), which has been shown to be a very effective lifesaving device in patients at risk of or with a history of ventricular arrhythmias. Finally, cardiologists also have some answer to the growing tide of heart failure with biventricular pacing to permit cardiac resynchronisation.

The use of catheter ablation for patients with supraventricular tachycardia, especially those with Wolff-Parkinson-White (WPW) syndrome, has been an established therapy for several years. The principal advances in catheter ablation have been in the treatment of AF and flutter and also in the treatment of ventricular tachycardia (VT) (table 1). The advances in ablation therapy for these conditions have been greatly helped by the advent of modern non-fluoroscopic mapping systems that allow the operator to view cardiac anatomy, electrophysiology and catheter positions without the need for fluoroscopy.

There have been a number of important studies on the management of AF published in the past few years. These studies have focused on the role of rhythm management—that is, striving to maintain sinus rhythm, compared with acceptance of AF with appropriate control of the ventricular rate. We will discuss the findings and implications of these studies later.

Device therapy indications (table 2) have also changed considerably in the past few years. ICDs have become both smaller and more sophisticated, making a routine implant little different from implanting a permanent pacemaker. The advent of biventricular pacing has provided cardiologists with a genuine chance to improve the quality and quantity of life in patients with symptomatic heart failure.

Ablation for supraventricular arrhythmias

Although an established therapy for many years, improvements in electrophysiological techniques have led to catheter ablation becoming first line therapy for most patients with AV nodal re-entrant tachycardia (AVNRT) or WPW, and for many patients with atrial flutter.

AVNRT

AVNRT is caused by re-entry within the AV node, using “fast” and “slow” pathways. Ablation of the slow pathway to cure AVNRT has become a comparatively straightforward and routine procedure. The most significant complication associated with slow pathway ablation is damage to the fast pathway and hence AV block requiring pacing. In one large series of more than 8000 patients, long term cure was achieved in 99% of patients with high grade AV block necessitating pacing occurring in only 0.4%. Catheter ablation has become the treatment of choice in patients with symptomatic AVNRT. Indeed, many patients and their physicians choose ablation as first line therapy to avoid the need for antiarrhythmic drug therapy.

WPW syndrome

Arrhythmias in the WPW syndrome are attributable to the presence of an additional atrioventricular connection, termed an “accessory pathway”. This commonly presents with atrioventricular re-entrant tachycardia (AVRT), which is often well tolerated. However, patients with WPW are at risk should they develop atrial fibrillation as the accessory pathway can conduct with WPW are at risk should they develop atrial fibrillation as the accessory pathway can conduct.

Abbreviations:
AF, atrial fibrillation; ICD, implantable cardiac defibrillator; WPW, Wolff-Parkinson-White syndrome; VT, ventricular tachycardia; VF, ventricular fibrillation; AVNRT, AV nodal re-entrant tachycardia; AVRT, atrioventricular re-entrant tachycardia; CTI, cavitricuspid isthmus; TaP, torse de pointes; LACA, left atrial cavitricuspid ablation; PVI, pulmonary vein isolation; RFA, radiofrequency catheter ablation; LVEF, left ventricular ejection fraction; EP, electrophysiological study; SCD, sudden cardiac death.
ventricular rates and ventricular fibrillation may ensue.

RF ablation of accessory pathways has become first line therapy for patients with symptomatic WPW as antiarrhythmic drugs are often ineffective and poorly tolerated. In a study of over 6000 patients from several centres, long term success rates were 98%. Serious complications (cardiac tamponade, AV block, coronary dissection, and stroke) were seen in 0.6% with only one fatality.1 The one time risk of catheter ablation seems to be lower than the cumulative lifetime risk associated with symptomatic WPW.

**Atrial flutter**

Atrial flutter is caused by a single wave of electrical activation that takes a consistent path around the atria. About 90% of atrial flutter involves a counterclockwise rotation in the right atrium. This pattern is often called “typical” or “common” atrial flutter by electrophysiologists. Typical atrial flutter results in a saw-tooth pattern in the inferior leads of the 12 lead ECG and a positive F wave in V1 (fig 1). The atrial rate is often around 300/min with a resulting ventricular rate of 150/ min. The circuit involved in typical flutter has been well defined and involves a narrow bridge of tissue (normally 1–2 cm) between the tricuspid valve and the inferior vena cava (IVC). This area is called the cavotricuspid isthmus (CTI). Drawing a line of ablation across this area effectively blocks the circuit for typical flutter.

Over the past 10 years the technique for flutter ablation has evolved and we now have well defined end points for the procedure.2-4 By achieving these end points long term success rates in prevention of recurrent atrial flutter are about 80%–90%. A prospective, randomised trial of medical treatment compared with catheter ablation as the first line therapy in atrial flutter has shown significantly better outcomes for patients treated by ablation. Patients treated by ablation had reduced atrial flutter, better wellbeing, and also a reduction in the onset of atrial fibrillation.2 The high success rate of ablation (with a low incidence of complications) suggests that increasing use should be made of ablation for this arrhythmia. Flutter ablation should be considered as first line therapy for three groups of patients: those with troublesome symptoms, those in whom ventricular rate control with drugs is suboptimal, and in those with left ventricular dysfunction as a result of persistent tachycardia.

The principal weakness of CTI ablation for atrial flutter is the subsequent onset of AF. Although atrial flutter and AF are different arrhythmias they are strongly connected. They share many predisposing factors and many patients will present with a combination of both atrial flutter and fibrillation. Patients with both arrhythmias who do especially well with flutter ablation are those in whom antiarrhythmic drug therapy (principally class Ic drugs such as flecaïnide) converts AF to flutter.5 After ablation the antiarrhythmic therapy must be continued to suppress further AF, but arrhythmia control is generally good with this strategy. In some other patients atrial flutter is an important precursor to AF and flutter ablation can then also be an effective antiarrhythmic strategy.

**ATRIAL FIBRILLATION**

There are two important areas that have changed in the management of AF over the past five years. The first is the publication of several studies addressing the issue of rate compared with rhythm control. The second is the use of ablation as a curative therapy for patients with AF.

**Rate compared with rhythm control**

Much of the treatment of AF in the past 30 years has been based on the “best guess” principle. AF is associated with heart disease and patients with AF were known to have an increased risk of stroke and an increased mortality,6 and therefore it was considered logical to attempt to restore sinus rhythm. However, the pursuit of sinus rhythm was not necessarily free from risks. The most important of these risks was the well recognised side effect of proarrhythmia from antiarrhythmic drugs.7 8 This led several groups to ask whether a default strategy of rhythm control was correct for all patients with AF or whether certain groups may be better served by a policy of accepting AF and controlling the ventricular rate.

<table>
<thead>
<tr>
<th>1st line therapy</th>
<th>2nd line after medical therapy</th>
<th>Occasionally useful</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wolff-Parkinson-White syndrome</td>
<td>Atrial flutter</td>
<td>Chronic AF</td>
</tr>
<tr>
<td>AV nodal re-entrant tachycardia</td>
<td>Paroxysmal AF</td>
<td>VT in the presence of structural heart disease</td>
</tr>
<tr>
<td>Atrial flutter (selected patients)</td>
<td>Atrial tachycardia</td>
<td></td>
</tr>
</tbody>
</table>

**Table 2 Evidence based indications for ICD therapy**

<table>
<thead>
<tr>
<th>Primary prevention (patients at risk of VT or VF)</th>
<th>Secondary prevention (patients resuscitated from VT or VF)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with class II or III heart failure of any oetiology with a LVEF &lt;35%</td>
<td>Cardiac arrest attributable to VT or VF not attributable to a transient or reversible cause</td>
</tr>
<tr>
<td>Patients with class III heart failure and a QRS duration of &gt;120 ms (these patients should be considered for a biventricular ICD)</td>
<td>Sustained VT or VF with haemodynamic compromise</td>
</tr>
<tr>
<td>Patients with LVEF &lt;30% at least one month after MI or 3 months after CABG</td>
<td>Sustained VT or VF without haemodynamic compromise but with LVEF &lt;35%</td>
</tr>
<tr>
<td>Non-sustained VT in patients with coronary disease, previous MI, LVEF &lt;35% and inducible VT at electrophysiological study</td>
<td></td>
</tr>
<tr>
<td>Familial condition with risk of SCD</td>
<td></td>
</tr>
<tr>
<td>Brugada syndrome</td>
<td></td>
</tr>
<tr>
<td>Long QT syndrome</td>
<td></td>
</tr>
<tr>
<td>HOCM</td>
<td></td>
</tr>
</tbody>
</table>
There have been four important studies of this aspect of AF management published in the recent few years. The largest of these studies was the AFFIRM study. Of the four studies, this study had the broadest inclusion criteria, and as treatment within each arm was at the discretion of the physician, the full range of treatments of AF. It is important to understand the inclusion criteria for each of the studies to allow us to focus on their applicability to the management of AF in clinical practice. For AFFIRM the inclusion criteria were patients aged >65 years, or with another risk factor for stroke or death, in whom the physician judged that AF would be an ongoing clinical problem. On this basis both patients with paroxysmal and persistent AF were enrolled. The other three studies only included patients with persistent AF. All patients had to be eligible for treatment with anticoagulants. Importantly, before randomisation the physician had to make a judgment that either treatment strategy would be acceptable to the patient. Many patients were enrolled during their first episode of AF (34%). A total of 4060 patients were enrolled and followed up for a mean of 3.5 years. The cross section of patients enrolled was similar to that seen in clinical practice here in the UK. The results are summarised below:

1. There was no difference in the primary outcomes of death and stroke during the time of follow up.
2. There was a slight trend to more strokes in the rhythm control arm, attributed to the tendency of physicians to withdraw anticoagulation when patients appeared to be stable in sinus rhythm. This provides an important lesson from this study. When a patient has an indication for anticoagulant treatment in the presence of AF even successful rhythm control does not remove the need for ongoing anticoagulation. A detailed review of indications for anticoagulation is beyond the scope of this article and the reader is referred to a recent review.
3. The main difference between the two treatment arms was that those in the rhythm control arm consumed more healthcare time and resources (for treatments such as DC cardioversion, pacemaker implantation, etc).
4. The risk of serious ventricular arrhythmia (torsade de pointes) was low (12 of 2030 or 0.8%) in the rhythm control arm, but still important.

The PIAF study compared rate control with diltiazem with rhythm control with amiodarone ± DC cardioversion in 252 patients with persistent AF (duration 7 to 360 days). Amiodarone was effective at maintaining sinus rhythm in 56% of patients at one year, compared with only 10% in sinus rhythm in the diltiazem group. The primary end point was symptoms related to AF and was no difference between the groups, although the rhythm control group had a slightly better exercise tolerance on a six minute walk test.

The RACE study investigated patients with recurrent AF after DC cardioversion. Patients were randomised to a policy of rate control compared with a rhythm control policy consisting of serial DC cardioversions with ongoing anti-arrhythmic drug treatment in an attempt to maintain sinus rhythm. A total of 522 patients were followed up for 2.3 years. The authors found no difference in a wide range of adverse events between the two groups.

The STAF study compared a strategy of rhythm control with rate control in patients with persistent AF. A total of 200 patients were recruited. There was no difference in the occurrence of major end points between the two arms of the study over three years. The authors did note, however, that most (18 of 19) of the serious end points occurred in AF.

As alluded to above, the STAF study and AFFIRM both showed an increased risk of serious adverse events for patients in AF, or put another way, a reduction in adverse events for patients who remained in sinus rhythm. Cardioversion of AF and maintenance of sinus rhythm has also previously been shown to result in better outcomes in two studies of antiarrhythmic drugs in heart failure patients. Studies of rate versus rhythm control in AF have failed to show an advantage to a rhythm control policy, despite the fact that patients in sinus rhythm do better than those who remain in AF.

This paradox is explained by the fact that the survival advantage of sinus rhythm is negated by a survival disadvantage when taking antiarrhythmic drug therapy. Perhaps when we have an effective alternative to antiarrhythmic drug therapy for the maintenance of sinus rhythm then we should readdress the issue of rate compared with rhythm control. However, current advice must be that if AF is well tolerated then a strategy of ventricular rate control is quite acceptable. It should also be emphasised that once a strategy of rate control is applied all antiarrhythmic drug treatment should be withdrawn.

Ablation for atrial fibrillation

Research into effective treatments for AF has flourished over the past decade. Increased understanding of the electrophysiology of AF from experimental work combined with findings from the catheter laboratory has led to effective treatments for AF. Effective control of AF was only initially possible by open heart surgery and the Maze procedure. Performing a catheter based Maze procedure for the control of AF was unsuccessful but led to the finding that in a large proportion of patients AF was triggered by ectopy originating in the pulmonary veins. After this finding Haissaguerre and
colleagues in Bordeaux went on to describe effective treatment of AF by radiofrequency ablation.20

Since the description of successful treatment of AF by catheter ablation, techniques have evolved considerably. Early enthusiasm was dented by the appreciation that extensive ablation in the left atrium was associated with a risk of stroke. Ablation within the pulmonary veins was also shown to result in pulmonary vein stenosis/occlusion. The target area for ablation has now moved to the atrial aspect of the pulmonary veins with improved results and reduced complications. The two principal techniques that have gained the most widespread acceptance are pulmonary vein isolation (PVI) as pioneered by the group in Bordeaux,21 22 and the left atrial circumferential ablation (LACA) technique as developed in Milan by Carlo Pappone.23 24 A recent comparison of the two techniques by another group has suggested a slightly higher efficacy of LACA over PVI25 although the recent addition of linear ablation in the left atrium to PVI has further increased its effectiveness. These two pioneering groups are reporting cure rates of up to 90% for patients with paroxysmal AF and only slightly lower for patients with persistent AF. The Bordeaux group have shown that, in patients with heart failure and AF, PVI improves left ventricular function, heart failure symptoms, and quality of life.26 Pappone’s group have shown improvements in all cause mortality, mainly attributable to a reduction in heart failure and ischaemic stroke, in those patients undergoing LACA compared with control.27 Although neither of these studies were randomised, they provide promising initial evidence that ablation for AF is safe and may have a beneficial effect on mortality. In this respect ablation seems to have an advantage over pharmacological rhythm control.

Outside of the pioneering centres, however, the results are not quite as good. Cure rates for paroxysmal AF are around 70%, but for persistent AF are somewhat less than 50%.28 Complication rates are also higher; a recent worldwide survey of complications after AF ablation showed an overall risk of significant complications of 6% including a 1%–2% risk of cardiac tamponade and a 1.3% risk of pulmonary vein stenosis.29 Although most complications can usually be managed successfully without serious long term sequelae, some of the rarer complications carry significant mortality, for example, atrio-oesophageal fistula.

Currently most interventional cardiac centres in the UK offer ablation for AF although patient selection and numbers vary considerably. Catheter ablation is certainly a treatment that should be considered for all patients who are symptomatic in AF and not adequately controlled on or are intolerant of antiarrhythmic medication.

VENTRICULAR TACHYCARDIA AND VENTRICULAR FIBRILLATION

Ventricular fibrillation (VF) and ventricular tachycardia (VT) are most commonly the consequence of coronary heart disease.30 They differ fundamentally from supraventricular tachycardias in that they are a common cause of sudden cardiac death (SCD). Their current management has been affected by the following:

1. The widespread adoption of implantable cardioverter defibrillators (ICDs) for first line prevention of VT and VF
2. The recognition of specific syndromes, for example, Brugada, long QT, which are associated with a high incidence of arrhythmic death attributable to VT and VF
3. The recognition that VT occurring in a structurally normal heart is potentially curable by radiofrequency catheter ablation (RFA), and that VT in the setting of structural heart disease is also amenable to effective treatment by RFA.

Key points: supraventricular arrhythmias

- Radiofrequency ablation is first line therapy for SVT
- Atrial flutter is curable by ablation in 90% of patients
- A rate control strategy with oral anticoagulation is acceptable for many patients with AF
- For patients with severe symptoms attributable to AF, ablation for AF is becoming more widely available

Figure 2 Chest radiograph showing a biventricular ICD in situ. Note the position of the device in the left pectoral region. A right ventricular lead with two shock coils, a right atrial lead, and a left ventricular lead (passed into an epicardial vein via the coronary sinus) are arrowed.
This section will focus on the long term management of patients who have been successfully resuscitated from an episode of VT or VF (secondary prevention) and those considered to be at high risk of VT or VF (primary prevention). For the acute treatment of VT and VF (advanced life support, cardioversion and acute antiarrhythmic drug therapy) the reader is referred to the current European Resuscitation Council advanced life support guidelines.25

ICD therapy for VT and VF

The management of patients who have survived a cardiac arrest attributable to VT or VF by pharmacological means has generally been disappointing. ICDs became commercially available in the 1980s and early 1990s. Three prospective trials (AVID,22 CASH,23 and CIDS24) compared ICD therapy with antiarrhythmic drug therapy, predominantly with amiodarone, in survivors of life threatening ventricular arrhythmias. A meta-analysis of these studies showed a 25% reduction in all cause mortality, which was entirely attributable a 50% reduction in sudden death. A second meta-analysis showed that the effect was primarily limited to those patients with left ventricular ejection fraction (LVEF) <35%.25

Together with the recognition of the efficacy of ICDs in patients surviving cardiac arrest, two clinical trials (MADIT I26 and MUSTT27) have shown a survival benefit from prophylactic insertion of an ICD in patients at risk of serious ventricular arrhythmias. Patients at risk were identified as those with the combination of prior myocardial infarction, impaired left ventricular function, non-sustained (NS)VT on Holter monitoring, and inducible VT or VF at electrophysiological (EP) study.

A subsequent trial, MADIT II,29 showed a survival benefit from prophylactic ICD implantation in patients with a history of myocardial infarction and LVEF <30%, regardless of the presence of NSVT or the results of EP testing. Recently the SCD-HeFT trial has shown improved survival in NYHA class II and III patients with a LVEF <35% receiving ICD implant regardless of the underlying aetiology of the left ventricular dysfunction.30

Although ICDs prevent arrhythmic death, many patients receiving them have advanced coronary disease and/or significant left ventricular dysfunction. Patients who would previously have succumbed to an arrhythmic death may now find themselves in the advanced stages of heart failure. Biventricular pacing has been shown to significantly improve symptoms and exert a modest effect on prognosis in patients with severe left ventricular impairment attributable to any cause (LVEF<35%) and class III or IV heart failure.31 When considering ICD therapy for such patients it may be appropriate to implant a device capable of biventricular pacing.

Table 2 summarises current evidence based indications for ICD implantation.32 Not all countries have fully adopted all of these ICD indications in view of concerns regarding cost and the medical infrastructure to support implantation and follow up.

ICD implantation is usually a straightforward procedure not dissimilar to a pacemaker implant. It can usually be carried out under local anaesthesia and sedation. The ventricular lead differs from a conventional pacing lead in that it contains coils that permit a high voltage shock to be delivered without local damage to the myocardium. As part of the ICD implant procedure, VF is induced and the ability of the device to detect and treat it tested. The risk of ICD implant is low, with pneumothorax and infection the commonest complications. The chest radiograph in figure 2 shows the usual site and size of the ICD generator as well as the lead positions. In this case a biventricular device has been implanted and a left ventricular lead is visible.

Modern ICDs have advanced algorithms that help to discriminate ventricular arrhythmias. Nevertheless, occasionally shock therapy can be delivered inappropriately, for example, during supraventricular tachycardias (for example, AF) or if a mechanical problem such as a lead fracture develops. Shock therapy is painful and may have profound psychological effects on the patient as well as having implications for social activities such as driving.

Antiarrhythmic drugs to prevent VT and VF

Antiarrhythmic drugs as a group have limited efficacy for preventing VT.33 34 Their present role is as an adjunct to ICD implantation to reduce number of shocks or in patients who do not wish to have an ICD. When used, empiric amiodarone is usually the drug of choice.35 36

A number of clinical trials have evaluated the efficacy of class Ia, Ib, Ic, and III drugs in the long term prevention of ventricular arrhythmias. None were placebo controlled for ethical reasons. A consistent message from these trials is that antiarrhythmic drugs may be pro-arrhythmic, especially in patients with coronary disease. Specifically, class Ic drugs, for example, flecainide, are contraindicated in patients with coronary disease. None of class I drugs are rarely used because of concerns about pro-arrhythmic effects.

The class III drugs amiodarone and sotalol are in any case more effective than class I drugs in the treatment of VT.37 38 39 However, the negatively inotropic effects of sotalol limit its use in patients with left ventricular impairment: in these
patients amiodarone is the drug of choice.\textsuperscript{32} The long term efficacy of newer class III drugs such as dofetilide has not yet been fully evaluated. Initial studies suggest that it is as effective as sotalol and better tolerated.\textsuperscript{48}

VT and VF in the structurally normal heart
Although the vast majority of cases of VT and VF occur in the setting of impaired left ventricular function, a number of conditions are recognised that cause these arrhythmias in the apparently structurally normal heart. It is important to recognise these arrhythmias as they may be precipitated by certain drugs, may be inherited, or may be amenable to catheter ablation.

Brugada syndrome
The Brugada syndrome was first described in 1992.\textsuperscript{49} It presents most often in young males, particularly in the Asian population.\textsuperscript{50} It is diagnosed by a typical ECG appearance consisting of partial right bundle branch block together with persistent ST elevation and inverted or bifid T waves in leads V\textsubscript{1} to V\textsubscript{3} (fig 3). Some patients do not have the typical ECG appearances at rest but they become apparent after the administration of a sodium channel blocking drug such as flecainide or ajmaline.\textsuperscript{51}

Patients with Brugada syndrome are at risk of SCD because of VT or VF.\textsuperscript{52} SCD may be the presenting feature; alternatively patients can present with syncopal episodes.\textsuperscript{52} The condition is inherited in an autosomal dominant fashion with variable expression. As a result, a significant number of asymptomatic patients are diagnosed through family screening.

The exact pathophysiological mechanism of SCD in these patients is not precisely known, although a significant proportion have abnormalities of sodium channel function.\textsuperscript{53} It is possible that changes in autonomic tone predispose towards arrhythmias as arrhythmias are often nocturnal.\textsuperscript{54} Antiarrhythmic drug therapy such as amiodarone or \(\beta\) block is ineffective at preventing SCD in Brugada syndrome.\textsuperscript{55} Sodium channel blocking drugs are pro-arrhythmic.\textsuperscript{51} ICD implantation is effective in selected patients.\textsuperscript{56} ICD implantation should be undertaken in patients with the Brugada syndrome who have survived SCD or who have syncope.\textsuperscript{56}
recorded QTc does not, therefore, exclude the diagnosis. 57 Exhibit variation and be normal at times. A single normal more apparent clinically in women, particularly when drug only associated with mutations LQT1 and LQT5. 60 The Jervell and Lange-Neilsen syndrome is autosomal recessive and associated with sensorineural deafness. It is still debate as to whether to implant ICDs in asymptomatic people with ECG changes characteristic of the syndrome. Electrophysiological testing has been advocated by some authors as useful in risk stratification, but more information is needed before this can be routinely recommended.

The presence of Brugada syndrome should be considered in any patient who has survived SCD and who has an apparently structurally normal heart. A normal resting ECG does not exclude the condition and these patients should have a challenge with a class Ic antiarrhythmic drug.

Long QT syndrome
The long QT syndrome represents a group of disorders of ventricular repolarisation, typified by prolongation of the QT interval on the ECG (fig 4A). The normal corrected QT interval (QTc) is less than 440 ms. Although by definition in patients with LQTS the QTc is usually &gt;440 ms, it may exhibit variation and be normal at times. A single normal recorded QTc does not, therefore, exclude the diagnosis. 57 LQTS is associated with an increased risk of a life threatening form of ventricular arrhythmia called torsade de pointes (TdP) (fig 4B). The longer the QT interval, the higher the risk of TdP. 58

LQTS is usually an inherited condition. Seven defects, predominantly in genes coding for cardiac ion channel proteins, have been identified and termed LQT1 to LQT7. The first three (LQT1, LQT2, and LQT3) are the commonest and most clinically relevant. 59 Two clinically defined syndromes exist. The Romano-Ward syndrome is an autosomal dominant condition with no extracardiac manifestations. It may be caused by any of the underlying genetic mutations. 60 The Jervell and Lange-Neilsen syndrome is autosomal recessive and associated with sensorineural deafness. It is only associated with mutations LQT1 and LQT5. 60

Patients often present with a cardiac event, usually syncope, aborted cardiac arrest, or SCD. 64 The condition is more apparent clinically in women, particularly when drug induced. 64 A significant number of cases are diagnosed by screening of family members.

The risk of SCD seems to be highest in those who have already experienced symptoms or who have reported ventricular arrhythmias. Events are frequently triggered by exercise, auditory stimuli, or emotion. 64 Assessing risk in apparently asymptomatic people, for example family members, is much more difficult. Current risk stratification is based on the genotype, the QT interval, and the sex of the patient. 65 Forms associated with deafness and with the LQT3 variant seem to be at particularly high risk. 62

LQTS may also be acquired. Metabolic abnormalities, principally hypokalaemia and hypomagnesaemia, bradycardia of any cause, and a large number of drugs have been implicated. The distinction between acquired and inherited LQTS is made more complicated by the variable penetrance exhibited by many of the genetic forms. Many patients appear to have a “forme fruste” of LQTS, which becomes clinically apparent only when the patient is exposed to a second factor, for example a drug that prolongs the QT interval. The ongoing drug induced arrhythmia risk evaluation (DARE) study has been designed to explore the interaction between genetic and environmental factors in drug induced ventricular arrhythmias.

Treatment in acquired LQTS consists first of removing the stimulus and correcting any metabolic/electrolyte abnormalities or bradycardia. Antiarrhythmic drugs must be avoided but β blockers, magnesium infusion, temporary pacing to prevent bradycardia, and phenytoin may be helpful in the acute setting. Patients with congenital LQTS need to avoid drugs that may precipitate TdP. A comprehensive, regularly updated list of such drugs can be found at http://www.qtdrugs.org. Patients should be instructed to check all new prescribed drugs at this site.

The mainstay of preventative treatment is β block, as sympathetic input is thought to be central to the initiation of arrhythmias. 64 All patients with congenital LQTS, whether symptomatic or asymptomatic should be treated with a β blocker in the absence of a contraindication. 64 About one third of patients with syncope or aborted SCD before β blocker therapy will experience another cardiac event during a five year period taking β blockers. 64 Atrial pacing may also prevent further cardiac events. 64 In patients presenting with

**Key points: ventricular arrhythmias**

- ICD implantation is first line therapy for prevention of VT and VF
- Drug therapy alone for VT is usually insufficient
- “Normal heart” VT is often amenable to catheter ablation
- There is an increasing recognition of inherited syndromes, for example, LQTS, Brugada that predispose to arrhythmic death in young people

![Figure 6](image-url)
cardiac arrest, the rate of repeat cardiac arrest is about 14% over a five year period of follow up and on this basis ICD implantation is recommended for all patients with LQTS who survive a cardiac arrest.62

All patients with a prolonged QTc on ECG or who present withTdP arrhythmias should be referred to a cardiac electrophysiologist for further investigation and screening of family members.

"Normal heart" VT

Ventricular tachycardia occurring in the presence of a structurally normal heart has two typical presentations. The first arises in the right ventricular outflow tract (RVOT), where it gives rise to a tachycardia with a typical left bundle branch block with strongly positive QRS in the inferior leads (fig 5).64 An important differential diagnosis for RVOT tachycardia is arrhythmogenic right ventricular dysplasia (ARVD). ARVD causes ventricular arrhythmias with similar tachycardia is arrhythmogenic right ventricular dysplasia however, that verapamil is never given to any patient with the ERVO. We do strongly recommend, pattern (fig 6). It is amenable to radiofrequency ablation and presents with a right bundle branch block, left axis deviation in the posterior fascicle of the left ventricle and in ventricular fibrillation. 

Catheter ablation for atrial fibrillation


The use of ICDs to prevent sudden cardiac death


Brugada syndrome


Long QT syndrome


CONCLUSION

The specialist management of arrhythmias has changed significantly over the past decade. This is partly because of a significant increase in the evidence base, principally in the rate compared with rhythm debate for the management of atrial fibrillation. The recognition of Brugada syndrome and further data to permit risk stratification of the long QT syndrome have also been invaluable. In addition, as technology has advanced ablation has found a significant role in the management of all arrhythmias.

Authors’ affiliations

M C S Hall, Manchester Heart Centre, Manchester, UK
D M Todd, The Cardiothoracic Centre, Liverpool, UK

Funding: none.

Conflicts of interest: none declared.

REFERENCES


